Quick Answer
GOLDENWELL BIOTECH, INC. reported Cash and Equivalents of $46.0 thousand for fiscal year 2022.
GOLDENWELL BIOTECH, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2022 | $46.0K | -78.5% |
| 2021 | $213.6K | -14.1% |
| 2020 | $248.6K | +0.8% |
| 2019 | $246.6K | — |
| 2018 | $0.00 | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| June 30, 2024 | $25.7K | — | -51.7% |
| December 31, 2023 | $53.2K | — | +24.2% |
| June 30, 2022 | $42.9K | -82.5% | -36.9% |
| March 31, 2022 | $67.9K | -72.7% | -68.2% |
| December 31, 2021 | $213.6K | -14.1% | -8.3% |
| September 30, 2021 | $232.9K | -7.0% | -5.1% |
| June 30, 2021 | $245.4K | -2.4% | -1.3% |
| March 31, 2021 | $248.6K | -1.2% | +0.0% |
- GOLDENWELL BIOTECH, INC. showed a decrease of -78.5% in Cash and Equivalents compared to the prior fiscal year.
- The most recent figure is from GOLDENWELL BIOTECH, INC.’s fiscal year 2022 report (Form 10-K), filed with the SEC on April 13, 2023.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: